Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV).
Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV).
复制标题
DOI：
10.1002/rmv.1984
复制
发表时间：
2018-07
影响因子：
11.1
通讯作者：
Sherman KE
中科院分区：
文献类型：
--
作者：
Blackard JT;Sherman KE
丙型肝炎病毒(丙型肝炎病毒)对乙肝病毒/丙型肝炎病毒混合感染患者的复制有抑制作用。最近，使用直接作用药物(DAA)治疗丙型肝炎病毒的患者中的乙肝病毒重新激活已成为一个重要的临床考虑因素。越来越多的病例报告和病例系列支持新的丙型肝炎治疗与乙肝病毒再激活之间的联系。然而，人们对促进重新激活的特定病毒特征知之甚少，因为对重新激活的乙肝病毒的功能表征很少进行。这篇综述提供了在DAA启动的背景下关于乙肝病毒重新激活的最新数据，并强调了现有的来自重新激活病毒的病毒基因组数据。目前对乙肝病毒再激活的功能研究在很大程度上受到以下因素的限制：病例的回溯性鉴定，与乙肝病毒再激活相关的基因组区域的标准化，以及缺乏建立与乙肝病毒再激活相关的特定病毒突变的非再激活对照。重要的是，这些测序研究中没有一项包括启动DAA后乙肝病毒重新激活的病例。虽然新的丙型肝炎病毒治疗方法已经彻底改变了对丙型肝炎病毒感染患者的治疗，但由于更常用的DAA处方，乙肝病毒重新激活的频率可能会增加。对乙肝病毒状态的预先判断和对乙肝病毒合并感染的周到管理将是必要的，这将提高患者的安全性并产生最佳的治疗结果。
Hepatitis C virus (HCV) is known to inhibit hepatitis B virus (HBV) replication in patients with HBV/HCV coinfection. Reactivation of HBV in patients treated for HCV with direct-acting agents (DAAs) has emerged recently as an important clinical consideration. A growing number of case reports and case series support the association between new HCV treatments and HBV reactivation. Yet, very little is known about the specific viral characteristics that facilitate reactivation as functional characterization of the reactivated HBV has been conducted only rarely. This review provides the most recent data on HBV reactivation in the context of DAA initiation and highlights the existing viral genomic data from reactivating viruses. Current functional studies of HBV reactivation are largely limited by the retrospective identification of cases, no standardization of genomic regions that are studied with respect to HBV reactivation, and the lack of inclusion of nonreactivating controls to establish specific viral mutations that are associated with HBV reactivation. Importantly, none of these sequencing studies included cases of HBV reactivation after initiation of DAAs. While new HCV treatments have revolutionized care for HCV infected patients, HBV reactivation will likely increase in frequency, as DAAs are more commonly prescribed. Pretreatment determination of HBV status and thoughtful management of HBV coinfections will be necessary and lead to improved patient safety and yield optimal treatment results.
登录
查看更多内容
DOI：
10.4103/1319-3767.98436
发表时间：
2012-07
期刊：
Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
影响因子：
--
作者：
Ferreira R;Carvalheiro J;Torres J;Fernandes A;Giestas S;Mendes S;Agostinho C;Campos MJ
通讯作者：
Campos MJ
影响因子：
14.2
作者：
Cerva, C.;Colagrossi, L.;Sarmati, L.
通讯作者：
Sarmati, L.
影响因子：
4.2
作者：
Chen, Q. Y.;Wang, X. Y.;Fang, Z. L.
通讯作者：
Fang, Z. L.
影响因子：
28.2
作者：
Ceccarelli, Laura;Salpini, Romina;Sarrecchia, Cesare
通讯作者：
Sarrecchia, Cesare
影响因子：
8.8
作者：
Coppola, Nicola;Loquercio, Giovanna;Petruzziello, Arnolfo
通讯作者：
Petruzziello, Arnolfo